|
|
|||||||||
Basic Science Investigations |
1 Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
2 Department of Tracer Kinetics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
3 Department of Radiopharmaceutical Chemistry, Health Sciences University of Hokkaido, Tobetsu, Japan
4 Department of Nuclear Medicine, Memorial SloanKettering Cancer Center, New York, New York
5 Division of Nuclear Medicine, Department of Radiology, Stanford University School of Medicine, Stanford, California
6 Department of Laboratory Medicine, University of Washington, Seattle, Washington
In tumors the process of apoptosis occurs over an interval of time after chemotherapy. To determine the best timing for detecting apoptosis in vivo with 99mTc-annexin V after chemotherapy, we examined the changes in 99mTc-annexin V accumulation over time in comparison with those of caspase-3 and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) expression level after cyclophosphamide treatment in an experimental model. Methods: Hydrazinonicotinamide (HYNIC)-annexin V was labeled with 99mTc (99mTc-annexin V). Rats were inoculated with allogenic hepatoma cells (KDH-8) into the left calf muscle. Eleven days after the inoculation, the rats were randomly divided into the group receiving a single dose of cyclophosphamide (150 mg/kg intraperitoneally) and the control group. 99mTc-Annexin V (18.5 MBq [0.5 mCi] per rat) was injected intravenously in the rats 4, 12, and 20 h after the treatment and also to the control rats (n = 5 in each group). Radioactivity in tissues was determined 6 h after 99mTc-annexin V injection. Immunostaining of caspase-3 and TUNEL were performed to detect apoptosis, and the rates of positively stained cells were calculated. Results: 99mTc-Annexin V accumulation in tumors significantly increased at 20 h (0.077 ± 0.007 [%ID/g] x kg, where %ID/g = percentage injected dose per gram) but not at 4 or 12 h (0.048 ± 0.008 and 0.052 ± 0.014 [%ID/g] x kg, respectively) after cyclophosphamide treatment. 99mTc-Annexin V accumulation in tumors and the rate of apoptotic cells determined by caspase-3 immunostaining and TUNEL were significantly higher in treated rats 20 h after cyclophosphamide treatment as compared with control rats. Conclusion: The effective detection of apoptotic tumor response with 99mTc-annexin V required 20 h after cyclophosphamide treatment in an experimental model. The present results provide an important basis for determining the best timing of annexin V imaging after the start of chemotherapy in a clinical setting.
Key Words: 99mTc-annexin V apoptosis cancer chemotherapy
Related articles in JNM:
This article has been cited by other articles:
![]() |
S. Rottey, G. Slegers, S. Van Belle, I. Goethals, and C. Van de Wiele Sequential 99mTc-Hydrazinonicotinamide-Annexin V Imaging for Predicting Response to Chemotherapy J. Nucl. Med., November 1, 2006; 47(11): 1813 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Huang, W.-Q. Ding, J. L. Vaught, R. F. Wolf, J. H. Morrissey, R. G. Harrison, and S. E. Lind A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties Blood, February 1, 2006; 107(3): 980 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takei, Y. Kuge, S. Zhao, M. Sato, H. W. Strauss, F. G. Blankenberg, J. F. Tait, and N. Tamaki Enhanced Apoptotic Reaction Correlates with Suppressed Tumor Glucose Utilization After Cytotoxic Chemotherapy: Use of 99mTc-Annexin V, 18F-FDG, and Histologic Evaluation J. Nucl. Med., May 1, 2005; 46(5): 794 - 799. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |